臨床婦人科産科67巻5号

2013年05月発行

今月の臨床 子宮体がん診療アップデート

治療のトピックス

2．子宮体がんの術後再発リスク評価と術後療法

著者： 進伸幸¹ 山上亘¹ 野村弘行¹ 阪埜浩司¹ 青木大輔¹

所属機関： ¹慶應義塾大学医学部産婦人科

ページ範囲：P.474 - P.484

文献概要

●早期体がん症例に対する術後療法としての放射線骨盤照射（EBRT）は全生存を改善せず，有害事象をもたらすことから，推奨されない．

●術後療法としての化学療法の標準基準はAP療法であり，JGOG2043（AP療法，TC療法，DP療法のRCT）の解析結果が待たれる．

●術後に化学療法と放射線療法を併用し，再発や原癌死に関するハザード比が低下したとする報告があり，また複数のRCTが進行中である．

参考文献

1） Pecorelli S : Revised FIGO staging for carcinoma of the vulva, cervix, and endometrium. Int J Gynecol Obstet 105 : 103─104, 2009

2） 日本産科婦人科学会・日本病理学会・日本医学放射線学会・日本放射線腫瘍学会（編） : 子宮体癌取扱い規約（第3版）進行期分類．pp4─11，金原出版社，東京，2012

3） 日本婦人科腫瘍学会（編） : 子宮体がん治療ガイドライン（2009年版），第2章 初回治療．pp25─70，pp14─15，金原出版社，東京，2009

4） Lewin SN, Herzog TJ, Barrena Medel NI, et al : Comparative performance of the 2009 international Federation of gynecology and obstetrics’ staging system for uterine corpus cancer. Obstet Gynecol 116 : 1141─1149, 2010

5） Lurain JR : Uterine cancer. In : Berek＆Novak's Gynecology 14th ed. pp1343─1401, Wiliams＆Wilkins, Philadelphia, 2007

6） Kato T, Watari H, Endo D, et al : New revised FIGO 2008 staging system for endometrial cancer produces better discrimination in survival compared with the 1988 staging system. J Surg Oncol 106 : 938─941, 2012

7） Garg G, Gao F, Wright JD, et al : Positive peritoneal cytology is an independent risk-factor in early stage endometrial cancer. Eur J Surg Oncol 38 : 230─237, 2013

8） Todo Y, Kato H, Minobe S, et al : A validation study of the new revised FIGO staging system to estimate prognosis for patients with stage IIIC endometrial cancer. Gynecol Oncol 121 : 126─130, 2011

9） Keys HM, Roberts JA, Brunetto VL, et al : A phase III trial of surgery with or without adjunctive external pelvic radiation therapy in intermediate risk endometrial adenocarcinoma : a Gynecologic Oncology Group study. Gynecol Oncol 92 : 744─751, 2004

10） Creutzberg CL, van Putten WL, Wárlám-Rodenhuis CC, et al : Outcome of high-risk stage IC, grade 3, compared with stage I endometrial carcinoma patients : the Postoperative Radiation Therapy in Endometrial Carcinoma Trial. J Clin Oncol 22 : 1234─1241, 2004

11） Susumu N, Sagae S, Udagawa Y, et al : Randomized phase III trial of pelvic radiotherapy versus cisplatin-based combined chemotherapy in patients with intermediate- and high-risk endometrial cancer : a Japanese Gynecologic Oncology Group study. Gynecol Oncol 108 : 226─233, 2008

12） Aalders J, Abeler V, Kolstad P, et al : Postoperative external irradiation and prognostic parameters in stage I endometrial carcinoma : clinical and histopathologic study of 540 patients. Obstet Gynecol 56 : 419─427, 1980

13） Creutzberg CL, van Putten WL, Koper PC, et al : Surgery and postoperative radiotherapy versus surgery alone for patients with stage-1 endometrial carcinoma : multicentre randomised trial. PORTEC Study Group. Post Operative Radiation Therapy in Endometrial Carcinoma. Lancet 355 : 1404─1411, 2000

14） ASTEC study group, Kitchener H, Swart AM, Qian Q, et al : Efficacy of systematic pelvic lymphadenectomy in endometrial cancer（MRC ASTEC trial） : a randomised study. Lancet 373 : 125─136, 2009

15） ASTEC/EN.5 Study Group, Blake P, Swart AM, Orton J, et al : Adjuvant external beam radiotherapy in the treatment of endometrial cancer（MRC ASTEC and NCIC CTG EN.5 randomised trials） : pooled trial results, systematic review, and meta-analysis. Lancet 373 : 137─146, 2009

16） Susumu N, Nomura H, Yamagami W, et al : Adjuvant chemotherapy for endometrial cancer（review）. In “Endometrial Cancer” ISBN : 978─953─307─1012─3, InTech, Croatia, 2012

17） Randall ME, Filiaci VL, Muss H, et al : Randomized phase III trial of whole-abdominal irradiation versus doxorubicin and cisplatin chemotherapy in advanced endometrial carcinoma : a Gynecologic Oncology Group study. J Clin Oncol 24 : 36─44, 2006

18） Maggi R, Lissoni A, Spina F, et al : Adjuvant chemotherapy vs radiotherapy in high-risk endometrial carcinoma : results of a randomised trial. Br J Cancer 95 : 266─271, 2006

19） Fleming GF, Brunetto VL, Cella D, et al : Phase III trial of doxorubicin plus cisplatin with or without paclitaxel plus filgrastim in advanced endometrial carcinoma : A Gynecologic Oncology Group study. J Clin Oncol 22 : 2159─2166, 2004

20） Miller D, Filiaci V, Fleming G, et al : Randomized phase III noninferiortiy trial of first line chemotherapy for metastatic or recurrent endometrial carcinoma : A Gynecologic Oncology Group study. The 2012 annual meeting on women's cancer. Late-breaking abstract 1. Gynecol Oncol

21） Nomura H, Aoki D, Takahashi F, et al : Randomized phase II study comparing docetaxel plus cisplatin, docetaxel plus carboplatin, and paclitaxel plus carboplatin in patients with advanced or recurrent endometrial carcinoma : a Japanese Gynecologic Oncology Group study（JGOG2041）. Ann Oncol 22 : 636─642, 2011

22） Homesley HD, Filiaci V, Gibbons SK, et al : A randomized phase III trial in advanced endometrial carcinoma of surgery and volume directed radiation followed by cisplatin and doxorubicin with or without paclitaxel : A Gynecologic Oncology Group study. Gynecol Oncol 112 : 543─552, 2009

23） Hogberg T, Signorelli M, de Oliveira CF, et al : Sequential adjuvant chemotherapy and radiotherapy in endometrial cancer--results from two randomised studies. Eur J Cancer 46 : 2422─2431, 2010

24） Hogberg T, Rosenberg P, Kristensen G, et al : A randomized phase-III study on adjuvant treatment with radiation（RT）±chemotherapy（CT）in early-stage high-risk endometrial cancer（NSGO─EC─9501/EORTC 55991）J Clin Oncol 25（18 suppl） : ＃5003（ASCO Annual Meeting Proceedings）2007